YiChang HEC ChangJiang Pharmaceutical : DISCLOSEABLE AND CONNECTED TRANSACTIONS AMENDMENTS TO THE NON-COMPETITION AGREEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

֝׹؇ජΈڗϪᖹٰุ΅Ϟࠢʮ̡

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

DISCLOSEABLE AND CONNECTED TRANSACTIONS AMENDMENTS TO THE NON-COMPETITION AGREEMENT

BACKGROUND

We have entered into a non-competition agreement with the then controlling shareholders of the Company (the ''2015 Controlling Shareholders'') in December 2015 (the ''2015 Non-Competition Agreement''), pursuant to which, the 2015 Controlling Shareholders agreed not to, and will procure their subsidiaries (other than the Group) not to, compete with us in our businesses and granted us the right to acquire the businesses of production and sales of active pharmaceutical ingredients and overseas sales of pharmaceutical products operated by the Parent Company and/or its subsidiaries (other than the Group) and certain future new businesses. For details, please refer to the prospectus issued by the Company on 15 December 2015.

As the Company and Sunshine Lake Pharma (being a controlled subsidiary of the Controlling Shareholders of the Company) will make more specific arrangements in relation to the business cooperation, the relevant contents of the 2015 Non-Competition Agreement will no longer be applicable to Sunshine Lake Pharma. Therefore, the Controlling Shareholders proposed to amend the 2015 Non-Competition Agreement to stipulate that the relevant contents of the 2015 Non-Competition Agreement will no longer be applicable to Sunshine Lake Pharma and that a new non-competition agreement will be entered into between Sunshine Lake Pharma and the Company.

AMENDMENTS TO THE NON-COMPETITION AGREEMENT 1 2021 Non-Competition Agreement

Date: 19 March 2021

Parties:

• . the Company

• . HEC Pharm Co., Ltd.* (宜昌東陽光藥業股份有限公司), a controlled subsidiary of the Controlling Shareholder of the Company and therefore a connected person of the Company

• . Yichang HEC Pharmaceutical Co., Ltd.* (宜昌東陽光健康藥業有限公司) (formerly known as Linzhi HEC Pharmaceutical Investment Co., Ltd.* (林芝東陽 光藥業投資有限公司)), a wholly-owned subsidiary of the Controlling Shareholder of the Company and therefore a connected person of the Company

• . Dongguan HEC Industrial Development Co., Ltd.* (東莞市東陽光實業發展有限公 司), a wholly-owned subsidiary of the Controlling Shareholder of the Company and therefore a connected person of the Company

• . Shenzhen HEC Industrial Development Co., Ltd.* (深圳市東陽光實業發展有限公 司), the Controlling Shareholder of the Company and therefore a connected person of the Company

• . Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd.* (乳源瑤族 自治縣寓能電子實業有限公司), the Controlling Shareholder of the Company and therefore a connected person of the Company

• . Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd.* (乳 源瑤族自治縣新京科技發展有限公司 ), the Controlling Shareholder of the Company and therefore a connected person of the Company

• . Ms. Guo Meilan (郭梅蘭), the Controlling Shareholder and the De Facto Controller of the Company and therefore a connected person of the Company

• . Mr. Zhang Yushuai (張寓帥)(Note1), the Controlling Shareholder and the De Facto Controller of the Company and therefore a connected person of the Company

Principal Amendments:

In view of a more specific arrangement made between the Company and Sunshine Lake Pharma in relation to the business cooperation and the entering into of a new non-competition agreement between the Company and Sunshine Lake Pharma, the 2021

Note 1:

The original signatory of the 2015 Non-Competition Agreement is Mr. Zhang Zhongneng (張中能). After the death of Mr. Zhang Zhongneng, his interest is succeeded by his son, Mr. Zhang Yushuai. Except for Mr. Zhang Yushuai, the signatories to the 2021 Non-Competition Agreement are the same as the signatories to the 2015 Non-Competition Agreement.

Non-Competition Agreement only excluded the contents involving Sunshine Lake Pharma (as a controlled subsidiary of the Controlling Shareholder). Other terms of the 2021 Non-Competition Agreement are the same as the terms of the 2015 Non-Competition Agreement.

2 Sunshine Lake Pharma Non-Competition Agreement

Date: 19 March 2021

Parties:

. the Company

. Sunshine Lake Pharma, a controlled subsidiary of the Controlling Shareholder of the Company and therefore a connected person of the Company

Subject Matters:

Scope of Non-Competition and Commitments

The principal business of the Company is the development and production of pharmaceutical products as well as the sales of pharmaceutical products within the PRC; the principal business of Sunshine Lake Pharma is the development and production of pharmaceutical products as well as the sales of pharmaceutical products outside the PRC. The scope of non-competition is the principal business of each of the parties as of the date of entering into this agreement.

The Company and Sunshine Lake Pharma undertake and procure their respective subsidiaries:

(1) not to directly or indirectly engage in or participate in, or assist or support any third party to engage in or participate in, either alone or with others, any business which competes or may compete, directly or indirectly, with the principal business of the counterparty and its subsidiaries in any form.

(2) during the validity period of the Sunshine Lake Pharma Non-Competition

Agreement, if each of the parties becomes aware of any relevant new business opportunity that competes or may compete, directly or indirectly, with the principal business of the counterparty, it shall give priority to offer such opportunity to the counterparty. If the counterparty decides not to accept the relevant new business opportunity for any reason, each of the parties may operate such new business opportunity itself.

Cooperation in Sales of Pharmaceutical Products within the PRC

Since Sunshine Lake Pharma is principally engaged in businesses such as the development and production of pharmaceutical products as well as the sales of pharmaceutical products outside the PRC, it has obtained, applied for or intended to apply for (1) national pharmaceutical approval numbers for its pharmaceutical products listed overseas; and (2) new national pharmaceutical approval numbers (the aforesaid domestic pharmaceutical products under the national pharmaceutical approval numbersare collectively referred to as the ''Domestic Cooperative Products''). In order to avoid competition with the Company and maximize the protection of the respective interests of both parties, they agreed to cooperate in the development of the Domestic Cooperative Products as follows:

• (1) Sunshine Lake Pharma shall be responsible for all research and development activities, submission of regulatory approval documents, completion of clinical trials, obtaining of pharmaceutical approval numbers and other cooperative arrangements for the Domestic Cooperative Products; Sunshine Lake Pharma shall have the right to choose to retain the relevant intellectual property rights, proprietary technologies, clinical trial approvals and pharmaceutical approval numbers for the domestic pharmaceutical products, and determine fair terms for the cooperation and transaction of the Domestic Cooperative Products through various market-based mechanisms (including in the form of negotiations with the Company, etc.) for commercialization (but the Company shall have the right not to accept such cooperation opportunities); if the Company determines to accept the cooperation opportunities, the Company may be given priority to obtain opportunities for the promotion and commercialization of the Domestic Cooperative Products within the PRC at nil consideration and cooperate and carry out transactions through the income sharing model.

• (2) The Company shall make a decision to accept the cooperation or not after receipt of the cooperation notice from Sunshine Lake Pharma. If the Company agrees to accept such domestic cooperation opportunity, it shall be responsible for all expenses in respect of promotion and commercialization of the Domestic Cooperative Products within the PRC; if the Company chooses not to accept the right to promote and commercialize one or more of the Domestic Cooperative Products within the PRC provided by Sunshine Lake Pharma (the ''Refused Products''), it shall notify Sunshine Lake Pharma within a reasonable period after receipt of the cooperation notice, which shall be deemed as not accepted by the Company when expired. Sunshine Lake Pharma may cooperate with third parties with the Refused Products at terms (including but not limited to consideration for license, sharing ratio and term) no more favorable than those offered to the Company.

• (3) The income distribution between Sunshine Lake Pharma and the Company in respect of the Domestic Cooperative Products shall be determined by mutual agreement between the parties based on the specific conditions of the products. The income distribution is mainly based on a sales income sharing model. The sales income sharing ratio and term between the parties are with reference to the industry practices, and the sharing period is determined to be the later of 10 years after the commercialization of the specific projects or the expiration date of the core patents of the projects; the sales income sharing ratio is proposed to be based on factors such as the stage of the specific products, the market size of the products and the potential market share, and the sharing ratio of the specific products is determined at a ratio no higher than that of comparable cases in the market in accordance with the respective internal review procedures performed by the parties prior to the launch and sales of the products on a case-by-case basis.

(4) Subject to the confirmation and agreement of Sunshine Lake Pharma and the

Company on the cooperation in sales of the domestic pharmaceutical products in the manner set out in this agreement, Sunshine Lake Pharma will not carry out the sales promotion and commercialization activities of the pharmaceutical products within the PRC, therefore, it will not constitute non-competition given a clear business scope of the parties.

3 Gift Agreement on Equity Interests

In order to further protect the interests of the Company, the shareholders of the Company, intend to grant 10% of the equity of Sunshine Lake Pharma (the ''Subject Equity'') to the Company through itself or a third party designated by it at nil consideration. Given that Sunshine Lake Pharma is introducing an external investor, the Subject Equity represents 10% equity interest in Sunshine Lake Pharma upon completion of this round of financing. The specific amount of registered capital corresponding to the Subject Equity shall be determined by the grantor and Sunshine Lake Pharma based on the actual capital introduction amount and its progress, and shall be determined and completed no later than 30 September 2021. If Sunshine Lake Pharma applies for Listing in the domestic and overseas securities markets, Controlling Shareholders shall guarantee that the proportion of equity interest of the Company in Sunshine Lake Pharma before the application for the Initial Listing shall not be less than 9%; otherwise Sunshine Lake Pharma shall further provide a supplementary gift to the Company until the Company holds 10% equity interest in it. After approval of the aforesaid amendments to the non-competition agreements and the revision of the relevant competition undertaking of the Parent Company, the said transfer shall become duly effective and the relevant taxes (if any) shall be borne by the parties thereto according to the law.

Date: 19 March 2021

Parties:

. Shenzhen HEC Industrial Development Co., Ltd.* (深圳市東陽光實業發展有限公 司), the Controlling Shareholder of the Company and therefore a connected person of the Company (as the grantor)

.

The Company (as the grantee)

(collectively, the ''Parties'')

Subject Matters:

The grantor, being an owner of equity interests in Sunshine Lake Pharma (the ''Subject Equity''), has agreed to transfer to the grantee with, on the terms and conditions under the Gift Agreement on Equity Interests, and the grantee has agreed to accept, on such terms and conditions, the Subject Equity that is free from any encumbrance and all rights attached to it. The grantor may designate a third party to transfer the Subject Equity to the grantee, which is deemed to be a transfer of the Subject Equity from the grantor to the grantee. Upon completion of the transfer, the grantee obtains theownership of the Subject Equity and has the right to manage, use, benefit from and dispose of the Subject Equity as well as to undertake the obligations, responsibilities and risks of the Subject Equity.

Conditions Precedent

The closing of the Subject Equity shall be conditional upon the satisfaction of the following conditions:

• (1) the approval from their respective internal approval authorities (such as the board of directors and/or the general meeting) has been obtained in accordance with the Articles of Association of the Parties and the relevant laws and regulations;

• (2) from the date of entering into the Gift Agreement on Equity Interests to the completion date (including the completion date), the representations, warranties and undertakings made by the Parties remain true, accurate and not misleading;

• (3) the matters relating to this gift of equity interests (including the amendments to the competition undertaking by the De Facto Controllers and the Controlling Shareholders and the execution of new non-competition agreements) have been considered and approved by the board of directors and the general meeting of the Company and the Parent Company.

• (4) the necessary approvals (if applicable) from external regulatory authorities relating to this gift of equity interests have been obtained.

The Parties shall complete the registration procedures for transferring the Subject Equity with the competent authority as soon as possible and no later than 30 September 2021 after complete satisfaction of the aforesaid conditions and completion of this round of financing . The completion date shall be the date of the registration by the competent authority.

In particular, if Sunshine Lake Pharma applies for the initial public offering of shares on a domestic and overseas stock exchange (the ''Application for the Listing''), the grantor shall guarantee that the proportion of equity interest in Sunshine Lake Pharma held by the grantee before the application for the initial listing of Shares of Sunshine Lake Pharma Listing shall not be less than 9%; if less than 9%, the grantor shall further provide a supplementary gift to the grantee until the grantee holds 10% equity interest in Sunshine Lake Pharma.

Establishment and Effectiveness of the Gift Agreement on Equity Interests

• (1) This Gift Agreement on Equity Interests is established on the date when the Parties stamp with their respective official chops and is signed by respective legal representatives (or authorized representatives).

• (2) This Gift Agreement on Equity Interests shall take effect from the date of approval by the internal approval authorities of the Parties and the Parent Company (such as the board of directors and/or the general meeting) in accordance with the Articles of Association of the Parties and the relevant laws and regulations.

REASONS FOR AND BENEFITS OF THE AMENDMENTS

As a pharmaceutical research and development platform of the Controlling Shareholders, Sunshine Lake Pharma is a company that engages in businesses such as the development and production of pharmaceutical products as well as the sales of pharmaceutical products outside the PRC, which has enriched the Company's product portfolio in a long run and contributed to the development of listed companies. However, due to the long research and development cycle, high investment, long return cycle and certain uncertainties, in order to solve the problem of research and development fund and accelerate the research and development progress, Sunshine Lake Pharma intends to introduce strategic investors to enhance the capital strength for independent development and promote listing in domestic and overseas securities markets. However, pursuant to the existing non-competition agreement, the Company is entitled to the priority and option right to the related business, assets and interests of Sunshine Lake Pharma, affecting the business stability and the asset independence of Sunshine Lake Pharma, the financing and subsequent capital operation, subsequent investment in and progress of research and development and thus the Company's continued opportunity to obtain more commercialization rights for domestic pharmaceutical products, which is not conducive to the long-term business development of the Company.

The Company is principally engaged in businesses such as the development and production of pharmaceutical products as well as the sales of pharmaceutical products within the PRC, and is not currently engaged in any overseas sales of pharmaceutical products. According to the existing non-competition agreement, the Company is entitled to the priority and option right to the overseas business, assets and interests of Sunshine Lake Pharma. However, since the production and sales activities of the overseas pharmaceutical business of Sunshine Lake Pharma are carried out around research and development, the system in respect of research and development, production and sales may not be divided. If the Company acquires the overseas pharmaceutical product business of Sunshine Lake Pharma, it is necessary to incorporate Sunshine Lake Pharma as a whole. Yet, Sunshine Lake Pharma is still mainly in the phase of new drug research and development with large unrecovered losses and a large pipeline of products under research, which requires a long-term and continuous investment in research and development. The exercise of such right will enhance the capital pressure of the Company and adversely affect its financial conditions.

Moreover, in order to reduce the Company's initial capital investment and accelerate the commercialization of research and development results, the Controlling Shareholders propose to procure Sunshine Lake Pharma and the Company to carry out business cooperation in respect of the domestic pharmaceutical products by way of supplementary undertaking. The income distribution of the Domestic Cooperative Products shall be determined by the mutual agreement between the parties based on the specific conditions of the products. The income distribution is mainly based on a sales income sharing model. This cooperation model is conducive to reducing the risk of initial investment and unrecoverable investment, which is more conducive to the Company's healthy and sustainable development.

In summary, the Directors (excluding all the independent non-executive Directors, who will give their opinion based on the recommendations from the independent financial adviser) are of the view that the terms of the amendments to the non-competition agreements, which have been agreed after arm's length negotiations, are on normal commercial terms, fair andreasonable and in the interests of the Company and the Shareholders as a whole; and the amendments are beneficial to accelerate the research and development progress of Sunshine Lake Pharma and provide the Company with more opportunities for commercialization of domestic pharmaceutical products, so as to reduce the Company's initial investment in the purchase of domestic pharmaceutical products from Sunshine Lake Pharma and the Company's operational risks, enhance the Company's capability of sustainable development and protect the interests of the Company and the Shareholders of the Company.

CORPORATE GOVERNANCE MEASURES

In order to ensure the compliance with the New Non-Competition Agreements, the Company will adopt the following corporate governance measures:

• (1) we will provide the independent non-executive Directors with the offer notice on the new business opportunity referred to us by the Controlling Shareholders and selling notice on pre-emptive rights or the cooperation notice from Sunshine Lake Pharma (as the case may be) within 7 days of receipt;

• (2) the independent non-executive Directors will review, on an annual basis, the compliance with the New Non-Competition Agreements by the Controlling Shareholders;

• (3) the Controlling Shareholders undertake to provide the Company with all the information necessary for the annual review conducted by the independent non-executive Directors. The independent non-executive Directors may engage professional advisors at the Company's expense to advise on matters relating to the New Non-Competition Agreements;

• (4) the independent non-executive Directors will report their findings on the compliance of the Controlling Shareholders with the New Non-Competition Agreements in our annual report; and

• (5) the Directors consider that the independent non-executive Directors have sufficient experience in assessing whether or not to take up any new business opportunities or exercise pre-emptive rights. In any case, as stated above, the independent non-executive Directors may appoint financial advisor or professional expert to provide advice, at the cost of the Company, in connection with the exercise or non-exercise of the option or pre-emptive right under the New Non-Competition Agreements.

Further, any proposed transaction between the Company, the Controlling Shareholders and the subsidiaries of the Controlling Shareholders will be required to comply with the requirements of the Listing Rules, including, where appropriate, the reporting, annual review, announcement and independent shareholders' approval requirements.

IMPLICATIONS UNDER THE LISTING RULES

As at the date of this announcement, the Parent Company, Shenzhen HEC Industrial Development Co., Ltd., Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd., Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd., Ms. Guo Meilan and Mr. Zhang Yushuai are the Controlling Shareholders of the Company, and therefore, they are the connected persons of the Company. Each of HEC Pharm Co., Ltd.,Dongguan HEC Industrial Development Co., Ltd., Yichang HEC Pharmaceutical Co., Ltd. and Sunshine Lake Pharma is a subsidiary of the Controlling Shareholders, and is therefore a connected person of the Company. Accordingly, the entering into of the Revised Non-Competition Agreements constitutes a connected transaction of the Company and is subject to the reporting, announcement and independent shareholders' approval requirements.

As the highest applicable percentage ratio in respect of the entering into of the transactions under the Revised Non-Competition Agreements is more than 5% but less than 25%, the entering into of the transactions under the Revised Non-Competition Agreements constitute a discloseable transaction of the Company and is subject to the reporting and announcement requirements under Chapter 14 of the Listing Rules.

By virtue of his position as a director and general manager of Shenzhen HEC Industrial Development Co., Ltd., Mr. Tang Xinfa, a non-executive Director, is considered to have a material interest in the entering into of the transactions under the Revised Non-Competition Agreements and has abstained from voting on the resolutions of the Board in relation to the entering into of the transactions under the Revised Non-Competition Agreements.

INFORMATION ON THE PARTIES

The Company

The Company is principally engaged in businesses such as the development and production of pharmaceutical products as well as the sales of pharmaceutical products within the PRC. The ultimate beneficial owners of the Company are Ms. Guo Meilan and Mr. Zhang Yushuai.

HEC Pharm Co., Ltd.

HEC Pharm Co., Ltd. is a company incorporated in the PRC and is principally engaged in the research and development, production and sales of macrolide antibiotics, antiviral and other active pharmaceutical ingredients. HEC Pharm Co., Ltd. is a controlled subsidiary of Shenzhen HEC Industrial Development Co., Ltd., the Controlling Shareholder of the Company. The ultimate beneficial owners of HEC Pharm Co., Ltd. are Ms. Guo Meilan and Mr. Zhang Yushuai.

Yichang HEC Pharmaceutical Co., Ltd.

Yichang HEC Pharmaceutical Co., Ltd. is a company incorporated in the PRC and is principally engaged in the investment, establishment and management of companies in the large health industry. Yichang HEC Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Shenzhen HEC Industrial Development Co., Ltd., the Controlling Shareholder of the Company. The ultimate beneficial owners of Yichang HEC Pharmaceutical Co., Ltd. are Ms. Guo Meilan and Mr. Zhang Yushuai.

Dongguan HEC Industrial Development Co., Ltd.

Dongguan HEC Industrial Development Co., Ltd. is a company incorporated in the PRC and is principally engaged in the investment, establishment and management of companies in various industries. Dongguan HEC Industrial Development Co., Ltd. is a wholly-ownedsubsidiary of Shenzhen HEC Industrial Development Co., Ltd., the Controlling Shareholder of the Company. The ultimate beneficial owners of Dongguan HEC Industrial Development Co., Ltd. are Ms. Guo Meilan and Mr. Zhang Yushuai.

Shenzhen HEC Industrial Development Co., Ltd.

Shenzhen HEC Industrial Development Co., Ltd. is a company incorporated in the PRC and is principally engaged in the investment and establishment of companies involving in various industries, domestic trading, import and export businesses. Shenzhen HEC Industrial Development Co., Ltd. is the holding company of the Company. The ultimate beneficial owners of Shenzhen HEC Industrial Development Co., Ltd. are Ms. Guo Meilan and Mr. Zhang Yushuai.

Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd.

Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd. is a company incorporated in the PRC and is principally engaged in the investment and establishment of companies involving in various industries (including materials and electronic components), domestic business, supply and sale of materials as well as purchase and sale of electronic products. Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd. is the holding company of Shenzhen HEC Industrial Development Co., Ltd. The ultimate beneficial owners of Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd. are Ms. Guo Meilan and Mr. Zhang Yushuai.

Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd.

Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd. is a company incorporated in the PRC and is principally engaged in the investment and establishment of companies involving in various industries (including materials and electronic components), domestic business, supply and sale of materials as well as purchase and sale of electronic products. Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd. is the holding company of Shenzhen HEC Industrial Development Co., Ltd. The ultimate beneficial owners of Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd. are Ms. Guo Meilan and Mr. Zhang Yushuai.

Sunshine Lake Pharma

Sunshine Lake Pharma is a company incorporated in the PRC. It is a pharmaceutical innovation research and development company principally engaged in businesses such as the research and development, pre-clinical and clinical development, drug registration, production and overseas sales of pharmaceutical products of small molecule innovative drugs, bio-innovative drugs and generic drugs. Sunshine Lake Pharma is a controlled subsidiary of Shenzhen HEC Industrial Development Co., Ltd., the Controlling Shareholder of the Company. The ultimate beneficial owners of Sunshine Lake Pharma are Ms. Guo Meilan and Mr. Zhang Yushuai.

EXTRAORDINARY GENERAL MEETING

The 2021 first extraordinary general meeting will be convened for the Independent Shareholders to, among other things, consider and, if thought fit, approve the entering into of the transactions under the Revised Non-Competition Agreements by way of ordinary resolution.

The Parent Company is required to abstain from voting on the resolution to be proposed at the 2021 first extraordinary general meeting to approve the entering into of the Revised Non-Competition Agreements and the transactions contemplated thereunder.

A circular containing, among other things, (i) further details of the entering into of the transactions under the Revised Non-Competition Agreements; (ii) the recommendation of the independent board committee in relation to the entering into of the transactions under the Revised Non-Competition Agreements; (iii) a letter of advice from Gram Capital to the independent board committee and the independent shareholders in relation to the entering into of the transactions under the Revised Non-Competition Agreements; and (v) other information as required by the Listing Rules is expected to be despatched to the shareholders on or before 15 April 2021.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

''2021 Non-Competition

Agreement''

the non-competition agreement entered into by and among the Company and HEC Pharm Co., Ltd.* (宜昌東陽光藥業 股份有限公司), Yichang HEC Pharmaceutical Co., Ltd.* (宜昌東陽光健康藥業有限公司), Dongguan HEC Industrial Development Co., Ltd.* (東莞市東陽光實業發展有限公司), Shenzhen HEC Industrial Development Co., Ltd.* (深圳市 東陽光實業發展有限公司 ), Ruyuan Yao Autonomous County Yuneng Electric Industrial Co., Ltd.* (乳源瑤族自 治縣寓能電子實業有限公司), Ruyuan Yao Autonomous County Xinjing Technology Development Co., Ltd.* (乳源 瑤族自治縣新京科技發展有限公司), Ms. Guo Meilan (郭梅 蘭) and Mr. Zhang Yushuai (張寓帥) on 19 March 2021

''Board''

the board of Directors of the Company

''Company''

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (宜昌東 陽光長江藥業股份有限公司), a company established in the PRC on 11 May 2015 as a joint stock company with limited liability

*

For identification purposes only

In this announcement, unless the context requires otherwise, the terms ''associate(s)'', ''connected person(s)'', ''connected transaction(s)'' and ''subsidiary (ies)'' shall have the meanings ascribed to them under the Listing Rules (as modified by the Stock Exchange from time to time).

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Tang Xinfa

Chairman

Hubei, the PRC

19 March 2021

As of the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.